CXCL13 and neoplasm: Since another team has demonstrated that this tumor-specific CD39+ CD4+ TILs population expresses CXCL13, PD-1 and TOX exhaustion makers and this population could contribute to tumor-specific CD8+ T cell proliferation and DC maturation through in situ reactivation with PD-1 blockade [184].